The drug is indicated for the treatment of HIV-1 infection and for pre-exposure prophylaxis to reduce the risk of HIV-1 infection in adults and adolescents. Lupin has received approval from the Food ...

The U.S. Food and Drug Administration approved the second drug to help prevent HIV infections on Thursday. Descovy is a PrEP or pre-exposure prophylaxis drug, which means the drug is taken daily to ...

It’s been over a decade since the Food and Drug Administration first approved a medication to prevent HIV. But the Centers for Disease Control and Prevention estimates just 30% of the 1.2 million ...

Preventing new HIV infections is becoming more difficult for nonprofit health clinics. Three things have changed: Pharmaceutical company Gilead Sciences Inc. ended a program last year that clinics ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Pre-exposure prophylactic, or ...

(Reuters) -A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat ...

Gilead stock fell early Friday as investors digested a first-quarter report driven by Descovy, rather than Yeztugo.

A Gilead Sciences drug that protects against HIV infection has won a highly anticipated FDA approval, becoming the first medication for HIV prevention available as a twice-yearly injection. The ...

A jury cleared Gilead Sciences of U.S. government allegations that it violated patents held by the Centers for Disease Control and Prevention on an HIV prevention drug. The government had sued Gilead ...

(Reuters) - An FDA advisory panel on Wednesday voted in favour of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex ...